Lee JY[Author] - Search Results

Year	Number of Results
1969	2
1970	1
1972	1
1973	1
1974	3
1975	4
1976	1
1977	2
1978	3
1979	4
1980	6
1981	7
1982	7
1983	9
1984	10
1985	9
1986	8
1987	8
1988	17
1989	24
1990	12
1991	23
1992	22
1993	19
1994	34
1995	22
1996	42
1997	40
1998	48
1999	64
2000	86
2001	103
2002	125
2003	146
2004	205
2005	285
2006	331
2007	323
2008	367
2009	448
2010	550
2011	676
2012	706
2013	813
2014	815
2015	851
2016	949
2017	950
2018	988
2019	1055
2020	1151
2021	1149
2022	1057
2023	1014
2024	1001
2025	584

1

Noncanonical PDK4 action alters mitochondrial dynamics to affect the cellular respiratory status.

Thoudam T, Chanda D, Sinam IS, Kim BG, Kim MJ, Oh CJ, Lee JY, Kim MJ, Park SY, Lee SY, Jung MK, Mun JY, Harris RA, Ishihara N, Jeon JH, Lee IK. Thoudam T, et al. Among authors: lee jy. Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2120157119. doi: 10.1073/pnas.2120157119. Epub 2022 Aug 15. Proc Natl Acad Sci U S A. 2022. PMID: 35969774 Free PMC article.

2

Editorial Comment.

Lee JY. Lee JY. J Urol. 2025 Apr;213(4):510. doi: 10.1097/JU.0000000000004382. Epub 2024 Dec 20. J Urol. 2025. PMID: 39704324 No abstract available.

3

Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.

Choi KH, Park YH, Lee JY, Jeong JO, Kim CJ, Yun KH, Lee HC, Chang K, Park MW, Bae JW, Doh JH, Cho BR, Kim HY, Kim W, Kim U, Rha SW, Hong YJ, Lee HJ, Ahn SG, Kim DI, Cho JH, Her SH, Jeon DS, Han SH, Lee JB, Lee CW, Kang D, Lee JM, Park TK, Yang JH, Lee SY, Choi SH, Gwon HC, Song YB, Hahn JY; SMART-CHOICE 3 investigators. Choi KH, et al. Among authors: lee jy. Lancet. 2025 Apr 12;405(10486):1252-1263. doi: 10.1016/S0140-6736(25)00449-0. Epub 2025 Mar 30. Lancet. 2025. PMID: 40174599 Clinical Trial.

4

Effects of virtual reality-based planar motion exercises on upper extremity function, range of motion, and health-related quality of life: a multicenter, single-blinded, randomized, controlled pilot study.

Park M, Ko MH, Oh SW, Lee JY, Ham Y, Yi H, Choi Y, Ha D, Shin JH. Park M, et al. Among authors: lee jy. J Neuroeng Rehabil. 2019 Oct 24;16(1):122. doi: 10.1186/s12984-019-0595-8. J Neuroeng Rehabil. 2019. PMID: 31651335 Free PMC article. Clinical Trial.

5

Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).

Ruan X, Bai W, Ren M, Kim T, Lee JY, Chuang FC, Wang PH, He W, Ma X, Miyazaki K, Song N, Wang X, Yu Q. Ruan X, et al. Among authors: lee jy. J Int Med Res. 2024 May;52(5):3000605241247684. doi: 10.1177/03000605241247684. J Int Med Res. 2024. PMID: 38818888 Free PMC article. Clinical Trial.

6

Correction: Ablation of dynamin-related protein 1 promotes diabetes-induced synaptic injury in the hippocampus.

Park G, Lee JY, Han HM, An HS, Jin Z, Jeong EA, Kim KE, Shin HJ, Lee J, Kang D, Kim HJ, Bae YC, Roh GS. Park G, et al. Among authors: lee jy. Cell Death Dis. 2021 Jun 1;12(6):565. doi: 10.1038/s41419-021-03841-2. Cell Death Dis. 2021. PMID: 34075023 Free PMC article. No abstract available.

7

Future regenerative therapies for corneal disease.

Lee JY, Knight RJ, Deng SX. Lee JY, et al. Curr Opin Ophthalmol. 2023 May 1;34(3):267-272. doi: 10.1097/ICU.0000000000000938. Epub 2023 Jan 5. Curr Opin Ophthalmol. 2023. PMID: 36602407 Review.

8

SPOP-mediated RIPK3 destabilization desensitizes LPS/sMAC/zVAD-induced necroptotic cell death.

Lee GE, Bang G, Byun J, Chen W, Jeung D, Cho H, Lee JY, Kang HC, Lee HS, Kim JY, Kim KD, Wu J, Nam SB, Kwon YJ, Lee CJ, Cho YY. Lee GE, et al. Among authors: lee jy. Cell Mol Life Sci. 2024 Nov 14;81(1):451. doi: 10.1007/s00018-024-05487-7. Cell Mol Life Sci. 2024. PMID: 39540935 Free PMC article.

9

Modulation of Immune Responses by Metabolic Reprogramming: The Key Role of Immunometabolism.

Park SG, Lee JY, Seo H, Hwang SS, Lee CK, Lee GR. Park SG, et al. Among authors: lee jy. Immune Netw. 2025 Feb 24;25(1):e15. doi: 10.4110/in.2025.25.e15. eCollection 2025 Feb. Immune Netw. 2025. PMID: 40078790 Free PMC article. No abstract available.

10

Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial.

Van Gorp T, Moore KN, Konecny GE, Leary A, García-García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Caruso G, Klasa-Mazurkiewicz D, Tromp J, Martin LP, Breuer S, Leath CA 3rd, Cibula D, Weroha SJ, Estévez-García P, O'Malley DM, Miller RE, Coffman L, Scandurra G, Berton D, Li L, Zagadailov E, Diver EJ, Trédan O, Hilpert F. Van Gorp T, et al. Among authors: lee jy. Lancet Oncol. 2025 Apr;26(4):503-515. doi: 10.1016/S1470-2045(25)00021-X. Lancet Oncol. 2025. PMID: 40179908 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,197 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,197 results

Results by year